Aprotinin revisited.

Abelardo DeAnda, Bruce D. Spiess

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

In 2008, we saw the withdrawal of aprotinin from the US markets after preliminary results from a large, randomized clinical trial in Canada. This drug, a potent antifibrinolytic, was used primarily in complex and/or redo cardiac surgery as an adjunct to decrease postoperative bleeding and complications. The Canadian study raised questions previously brought up in similar studies-does aprotinin increase the risk of mortality and renal failure after cardiac surgery? Recently, a re-review of the Canadian data noted flaws in the study, as well as in the interpretation of the results. The present review revisits the aprotinin controversy.

Original languageEnglish (US)
Pages (from-to)998-1002
Number of pages5
JournalThe Journal of Thoracic and Cardiovascular Surgery
Volume144
Issue number5
StatePublished - 2012
Externally publishedYes

Fingerprint

Aprotinin
Thoracic Surgery
Antifibrinolytic Agents
Canada
Renal Insufficiency
Randomized Controlled Trials
Hemorrhage
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Aprotinin revisited. / DeAnda, Abelardo; Spiess, Bruce D.

In: The Journal of Thoracic and Cardiovascular Surgery, Vol. 144, No. 5, 2012, p. 998-1002.

Research output: Contribution to journalReview article

DeAnda, A & Spiess, BD 2012, 'Aprotinin revisited.', The Journal of Thoracic and Cardiovascular Surgery, vol. 144, no. 5, pp. 998-1002.
DeAnda, Abelardo ; Spiess, Bruce D. / Aprotinin revisited. In: The Journal of Thoracic and Cardiovascular Surgery. 2012 ; Vol. 144, No. 5. pp. 998-1002.
@article{e02c9f3b29a34d38aa8d312da41f0c90,
title = "Aprotinin revisited.",
abstract = "In 2008, we saw the withdrawal of aprotinin from the US markets after preliminary results from a large, randomized clinical trial in Canada. This drug, a potent antifibrinolytic, was used primarily in complex and/or redo cardiac surgery as an adjunct to decrease postoperative bleeding and complications. The Canadian study raised questions previously brought up in similar studies-does aprotinin increase the risk of mortality and renal failure after cardiac surgery? Recently, a re-review of the Canadian data noted flaws in the study, as well as in the interpretation of the results. The present review revisits the aprotinin controversy.",
author = "Abelardo DeAnda and Spiess, {Bruce D.}",
year = "2012",
language = "English (US)",
volume = "144",
pages = "998--1002",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Aprotinin revisited.

AU - DeAnda, Abelardo

AU - Spiess, Bruce D.

PY - 2012

Y1 - 2012

N2 - In 2008, we saw the withdrawal of aprotinin from the US markets after preliminary results from a large, randomized clinical trial in Canada. This drug, a potent antifibrinolytic, was used primarily in complex and/or redo cardiac surgery as an adjunct to decrease postoperative bleeding and complications. The Canadian study raised questions previously brought up in similar studies-does aprotinin increase the risk of mortality and renal failure after cardiac surgery? Recently, a re-review of the Canadian data noted flaws in the study, as well as in the interpretation of the results. The present review revisits the aprotinin controversy.

AB - In 2008, we saw the withdrawal of aprotinin from the US markets after preliminary results from a large, randomized clinical trial in Canada. This drug, a potent antifibrinolytic, was used primarily in complex and/or redo cardiac surgery as an adjunct to decrease postoperative bleeding and complications. The Canadian study raised questions previously brought up in similar studies-does aprotinin increase the risk of mortality and renal failure after cardiac surgery? Recently, a re-review of the Canadian data noted flaws in the study, as well as in the interpretation of the results. The present review revisits the aprotinin controversy.

UR - http://www.scopus.com/inward/record.url?scp=85027944076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027944076&partnerID=8YFLogxK

M3 - Review article

C2 - 22795461

AN - SCOPUS:85027944076

VL - 144

SP - 998

EP - 1002

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 5

ER -